Updates in fluorodeoxyglucose positron emission tomography (18FDG-PET) in the diagnosis and management of cardiac sarcoidosis
Progress in Cardiovascular Diseases · 2025
DOI: 10.1016/j.pcad.2025.08.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2025. Verfasst von Ellen Kronzer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Sarcoidosis, Fluorodeoxyglucose F18, Cardiomyopathies, Radiopharmaceuticals. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben.
Abstract (Originalsprache)
Cardiac sarcoidosis (CS) is an infiltrative cardiomyopathy characterized by non-caseating granulomatous inflammation that results in significant morbidity and mortality. It has become increasingly recognized over the past several decades; however, diagnosis remains challenging due to its heterogeneous nature and limited diagnostic yield of endomyocardial biopsy. As such, there has been increasing reliance on advanced cardiac imaging to aid in the diagnosis and management of CS. Fluorodeoxyglucose positron emission tomography (18FDG-PET) has emerged as the most robust imaging modality and remains the preferred method for assessing active inflammation, treatment response, and surveillance. Nevertheless, it requires meticulous patient preparation and image acquisition to ensure optimal imaging and interpretation. This article aims to provide a comprehensive review of the various imaging modalities used for the diagnosis of CS, with a particular focus on the intricacies of 18FDG-PET, including the latest advancements in patient preparation and study interpretation. Other future directions for the diagnosis and management of CS will also be discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: Bois.John@mayo.edu.
Zitieren
APA
Kronzer, E., Hagan, G., Ledet, C., Knott, J., Bois, J., Askew, J. W., & Chareonthaitawee, P. (2025). Updates in fluorodeoxyglucose positron emission tomography (18FDG-PET) in the diagnosis and management of cardiac sarcoidosis. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2025.08.004
Vancouver
Kronzer E, Hagan G, Ledet C, Knott J, Bois J, Askew JW, et al. Updates in fluorodeoxyglucose positron emission tomography (18FDG-PET) in the diagnosis and management of cardiac sarcoidosis. Progress in Cardiovascular Diseases. 2025. doi:10.1016/j.pcad.2025.08.004
BibTeX
@article{Kronzer2025,
author = {Kronzer, Ellen and Hagan, Grace and Ledet, Caroline and Knott, Jonathan and Bois, John and Askew, J Wells and Chareonthaitawee, Panithaya},
title = {Updates in fluorodeoxyglucose positron emission tomography (18FDG-PET) in the diagnosis and management of cardiac sarcoidosis},
journal = {Progress in Cardiovascular Diseases},
year = {2025},
doi = {10.1016/j.pcad.2025.08.004}
}
EUVIMED